Category: St. Jude Medical
Newly minted Conceptus CEO Grossman predicts that an upcoming mandate to provide free contraception as part of health care reform will prove to be an "inflection point" for his firm's Essure female sterilization procedure; also, Bard's Irish profits more than doubled in 2010; Computer Sciences Corp. to write off $1.5B U.K. EMR investment; J&J CEO Weldon makes Dealbook's worst CEOs list; BSX sells Florida site for a reported $15m; New 52-week highs for Abbott, Amgen and Intuitive Surgical; and analysts' ups and downs.
The Affordable Care Act's provision covering contraception could be an "inflection point" for Conceptus (NSDQ:CPTS) and its Essure female sterilization system, new CEO Keith Grossman told Leering Swann analysts last month.
, Baxter International
, Boston Scientific
, C.R. Bard
, Computer Sciences Corp.
, Conceptus Inc.
, Golden Meditech Holdings Ltd.
, Hologic Inc.
, Intuitive Surgical Inc.
, Johnson & Johnson
, Kensey Nash Corp.
, St. Jude Medical
, Abbott Laboratories
Bin Laden's kidney disease, St. Jude's CEO slams Medtronic, med-tech to save Steve Jobs, DNA tests show incest and Bill Hawkins on leaving MDT were the most popular medical device stories of 2011.
Welcome to MassDevice's annual audit of the ups, downs and in-betweens of the year that was. For the medical device industry, 2011 was more or less defined by a nagging sense of uncertainty that hung over the world's med-tech companies like a grey cloud above a summer picnic.
But what did we learn from all the conjecture? In truth, not much. The year ends much as it began, full of questions with no cut and dry answers as we turn the calenFdar over into the new year.
Sen. Scott Brown, the junior senator and Republican from Massachusetts, garners big bucks in campaign donations from med-tech makers as he rallies against the device tax and gears up for re-election.
Sen. Scott Brown (R-Mass.), a vocal advocate for the medical device industry, has collected thousands in individual donations from med-tech executives and industry political action committees during the 2011-2012 campaign, federal documents show.
Between January and October, Brown received more than $42,000 in PAC donations and individual contributions from medical device groups and executives as he campaigned for re-election.
The top three medical device stories for December 16, 2011.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com's coverage highlights our three biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
The FDA slaps St. Jude's now-defunct Riata device with Class I status after the company announces the defibrillator leads failed more often than previously reported.
The FDA slapped St. Jude Medical Inc.'s (NYSE:STJ) Riata with a Class I recall after the company said the defibrillator leads failed more frequently than previously reported.
Shares of Kensey Nash dive today after it revokes its fiscal outlook for all of fiscal 2012 over a royalty dispute with St. Jude Medical over the Angio-Seal device.
Shares of Kensey Nash Corp. (NSDQ:KNSY) are down nearly 18% today after the company revoked its guidance for fiscal 2012 over a royalties dispute with St. Jude Medical (NYSE:STJ).
Olympus Corp. restates its finances for the past 5 years after getting caught cooking the books to dodge investment losses, taking a $1.1 billion hit just in time to evade a de-listing from the Tokyo exchange; also, Medtronic gets in on the burgeoning Chinese device market; St. Jude OKs $300M share buyback; Abbott invests $11.4M in India; new 52-week lows for Boston Scientific and NuVasive; and analysts' ups and downs.
Olympus Corp.'s (TYO:7733) re-stated finances for the past 5 years include a $1.1 billion hit from its 13-year scheme to hide investment losses with specious M&A consulting fees.
The endoscopy giant made the filings with Japanese regulators after being caught red-handed cooking its books to hide the fees, just avoiding a de-listing from the Tokyo stock exchange but fueling rumors that it will need to merge, sell a division or two or raise some cash to keep itself alive.